Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study
Authors
Keywords
-
Journal
LUNG CANCER
Volume 180, Issue -, Pages 107213
Publisher
Elsevier BV
Online
2023-04-22
DOI
10.1016/j.lungcan.2023.107213
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
- (2022) B.C. Cho et al. ANNALS OF ONCOLOGY
- Lazertinib: First Approval
- (2021) Sohita Dhillon DRUGS
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
- (2021) Byoung Chul Cho et al. Future Oncology
- A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
- (2021) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
- (2020) Charles L. Loprinzi et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors
- (2020) Misako Nagasaka et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overview of current systemic management of EGFR-mutant NSCLC
- (2018) W -H Hsu et al. ANNALS OF ONCOLOGY
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials
- (2016) J. C.-H. Yang et al. ANNALS OF ONCOLOGY
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now